News

Exercise-induced bronchoconstriction (EIB) is typically characterized by shortness of breath, cough, wheeze and chest tightness brought on by exercise. In clinical studies, a single tablet of Singulair 10mg

The drug has been cleared in 10mg, 20mg, 40mg and 80mg strengths, with 180-day market exclusivity in the US healthcare system for the 80mg strength. The FDA has

Despite advances in the treatment of acute coronary syndromes, the risk of recurrent cardiovascular events remains substantial. The effectiveness and safety of the drug had not previously been

The study results indicate bioequivalent pharmacokinetics between ANX-514 and the FDA-approved version of Taxotere. Furthermore, ANX-514, administered intravenously, did not cause hypersensitivity reactions in this study, as opposed

ALKS 27 is an inhaled formulation of trospium chloride based on Alkermes' AIR pulmonary technology. The study will assess the safety, tolerability, pharmacokinetics and efficacy of single doses

The receipt of FDA clearance triggers a milestone payment to the previous Montigen shareholders of $10 million, to be paid in SuperGen common stock. The phase I accelerated

The trial will investigate the efficacy and safety of three oral doses of VSF-173 for the treatment of induced excessive sleepiness in approximately 60 healthy male and female

The results are based on achievement of the primary efficacy endpoint of the trial, Summary of Pain Intensity Difference (SPID), compared to placebo. The results demonstrated that patients

XP13512 demonstrated statistically significant improvements compared to placebo on both of the co-primary endpoints of the trial and was well tolerated. The co-primary endpoints for the clinical trial